Entera Bio (NASDAQ:ENTX) Shares Gap Down – Here’s What Happened

Shares of Entera Bio Ltd. (NASDAQ:ENTX) gapped down prior to trading on Tuesday. The stock had previously closed at $2.94, but opened at $2.79. Entera Bio shares last traded at $3.1070, with a volume of 38,567 shares trading hands.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ENTX. Cantor Fitzgerald initiated coverage on shares of Entera Bio in a report on Tuesday, September 22nd. They set an “overweight” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a report on Thursday, October 15th. Lifesci Capital began coverage on shares of Entera Bio in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price objective on the stock. Leerink Partners started coverage on shares of Entera Bio in a research report on Friday, September 18th. They issued an “outperform” rating and a $9.00 price objective for the company. Finally, Guggenheim assumed coverage on Entera Bio in a research note on Thursday, September 24th. They set a “buy” rating and a $11.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Entera Bio has a consensus rating of “Moderate Buy” and a consensus price target of $9.60.

Entera Bio Trading Up 1.0%

The business has a 50 day simple moving average of $2.89 and a two-hundred day simple moving average of $2.06. The stock has a market cap of $530.46 million, a price-to-earnings ratio of -8.71 and a beta of 1.40.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Research analysts anticipate that Entera Bio Ltd. will post -0.40 EPS for the current fiscal year.

Institutional Trading of Entera Bio

A hedge fund recently raised its position in Entera Bio stock. Renaissance Technologies LLC boosted its stake in Entera Bio Ltd. (NASDAQ:ENTX) by 338.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 473,442 shares of the company’s stock after acquiring an additional 365,441 shares during the period. Renaissance Technologies LLC owned 0.96% of Entera Bio worth $526,000 at the end of the most recent reporting period. 14.11% of the stock is currently owned by institutional investors.

About Entera Bio

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered biologic medicines. The company’s proprietary platform is designed to enable the oral administration of large-molecule therapies, including peptides and proteins that are traditionally delivered by injection.

Entera Bio’s pipeline has included EB613, an oral formulation of parathyroid hormone fragment (teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral parathyroid hormone product intended for hypoparathyroidism.